We found that high-risk patients had a worse OS than low-risk patients in the IDH-mutant GBM cohort (median OS: 13.9 versus 33.6 months; HR for OS: 2.869 (1.351–6.091); P=0.0061; Supplementary Figure 1). The gene discussed is IDH2; the disease is glioblastoma.